79222-05-2

Upstream product

• 13414-95-4 4-keto-4,5,6,7-tetrahydrothianaphthene 
• 4653-08-1 4-oxo-4-thiophen-2-yl-butyric acid 
• 58372-62-6 4-(thiophen-2-yl)butanoyl chloride 
• 4653-11-6 2-thiophenebutyric acid 

Downstream Products

• 17402-83-4 benzo[B]thiophen-4-ylamine 
• 2164-24-1 trans-2-ethylcyclohexylamine 
• 4751-61-5 4,6,7,8-Tetrahydro-4H-thieno[3,2-b]azepin-5-one 
• 4751-59-1 5,6,7,8-tetrahydro-4H-thieno[3,2-c]azepine-4-one 
• 58094-17-0 4,5,6,7-tetrahydrobenzo[b]thiophen-4-amine 
• 180340-57-2 5,6,7,8-tetra-hydro-4H-thieno[3,2-b]azepine 
• 94252-22-9 6,7-dihydro-5H-benzo[b]thiophene-4-one O-tosyloxime 
• 180340-58-3 (4-nitrophenyl)(5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-4-yl)methanone 
• 180340-59-4 4-(4-Nitrobenzoyl)-4,5,6,7-tetrahydro-8H-thieno[3,2-b]-azepin-8-one 
• 180992-34-1 4-(2-chloro-4-aminobenzoyl)-5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepine 
• 180992-33-0 4-(2-Chloro-4-nitrobenzoyl)-5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepine 
• 180992-32-9 2-chloro-4-(4-aminobenzoyl)-5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepine 
• 180340-61-8 2-Chloro-4-(4-nitrobenzoyl)-5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepine 
• 276867-99-3 6-(4-aminobenzoyl)pyrazolo[3,4-d]thieno[3,2-b]azepine 

Relevant academic research and scientific papers

The synthesis and vasopressin (AVP) antagonist activity of a novel series of N-Aroyl-2,4,5,6-tetrahydropyrazolo-[3,4-d]thieno[3,2-b]azepines

Synthesis and SAR of N-[4-[(4,5-dihydropyrazolo[3,4-d]thieno[3,2-b]azepin-6(2H)-yl)carbonyl]phenyl]be nzamides as arginine vasopressin (AVP) receptor antagonists are discussed. Potent orally active AVP receptor antagonists are produced when the benzamide moiety contains a phenyl group at the 2-position. Similar analogues of 4,6,7,8-tetrahydro-5H-thieno[3,2-b]azepine and VPA-985 are reported. (C) 2000 Elsevier Science Ltd. All rights reserved.

Regioselective synthesis of heterocycles containing nitrogen neighboring an aromatic ring by reductive ring expansion using diisobutylaluminum hydride and studies on the reaction mechanism

(Chemical Equation Presented) A systematic investigation of the reductive ring-expansion reaction of cyclic ketoximes fused to aromatic ringswith diisobutylaluminum hydride (DIBALH) is described. This reaction regioselectively afforded a variety of five- to eight-membered bicyclic heterocycles or tricyclic heterocycles containing nitrogen neighboring an aromatic ring, including indoline, 1,2,3,4,5,6-hexahydrobenz[b]azocine, 3,4-dihydro-2H-benzo[b] [1,4]oxazine, 2,3,4,5-tetrahydrobenzo[b][1,4]thiazepine, 1,2,3,4,5,6- hexahydroazepino[3,2-b]-indole, 2,3,4,5-tetrahydro-1H-benzothieno[2,3-b]azepine, 2,3,4,5-tetrahydro-1H-benzothieno[3,2-b]-azepine, 5,6-dihydrophenanthridine, and 5,6,11,12-tetrahydrodibenz[b, f]azocine. The reaction mechanism leading to the rearrangement was investigated on the basis of the restricted Becke three-parameter plus Lee-Yang-Parr (B3LYP) density functional theory (DFT) with the 6-31G (d) basis set. It was found that the reaction proceeds through a three-centered transition state via a stepwise mechanism because the potential energy curve along the intrinsic reaction coordinate (IRC) had twomaxima (saddle points; TS1 and TS2) and the partial phenonium cation intermediate C. In addition to cyclic ketoximes fused to aromatic rings, the reactions of various cyclic and acyclic ketoximeswere examined to investigate preference of migrating group. It was found that themore electron-rich group migrated preferentially to give the corresponding secondary amines.

Non-peptide oxytocin agonists

The first non-peptide, low molecular weight agonists of the hormone oxytocin (OT) are reported. The most potent compound, 39, showed an EC 50 = 33 nM and was selective for the OT receptor. A library of compounds targeted to the vasopressin/oxytocin family of receptors was screened for activity at a cloned human oxytocin receptor using a reporter gene assay. Potency and selectivity were optimised to afford compound 39, EC50 = 33 nM. This series of compounds represents the first disclosed, non-peptide, low molecular weight agonists of the hormone oxytocin (OT).

Further characterization of structural requirements for ligands at the dopamine D2 and D3 receptor: Exploring the thiophene moiety

The present study describes the synthesis and in vitro pharmacology of a novel series of dopaminergic agents in which the classical phenylethylamine pharmacophore is replaced by a thienylethylamine moiety. In general, the novel compounds showed a moderate

Regioselective synthesis of several heterocyclic fused azepines using diisobutylaluminum hydride

5,6,7,8-Tetrahydrothieno[3,2-b]azepine,5,6,7,8-tetrahydro-1H-furo[3,2-b] azepine, and 1,4,5,6,7,8-hexahydropyrrolo[3,2-b]azepine were synthesized by the ring expansion reaction of heterocyclic fused cyclohexanone oximes with diisobutylaluminum hydride (DIBAH). The mechanism of the reaction was different from that of Beckmann rearrangement.

Heterocyclic-fused lactams promote release of growth hormone

There are disclosed certain novel compounds identified as heterocyclic-fused lactams which promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible